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We report an interesting case of a 17-year-old normal-statured female who was diagnosed with congenital panhypopituitarism
due to pituitary hypoplasia at the presentation of bilateral slipped capital femoral epiphysis. We emphasized the importance of
endocrinologic evaluation in patients with atypical slipped capital femoral epiphysis to prevent potential complication of adrenal
crisis during surgery. This case also demonstrates growth without growth hormone which resulted in a delay in diagnosis of
congenital hypopituitarism in this patient.
Copyright © 2009 S. A. Bowden and K. E. Klingele. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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1.Introduction
Slipped capital femoral epiphysis (SCFE) is a common
hip disorder in adolescents, characterized by medial and
posterior displacement of the proximal femoral epiphysis on
themetaphysis.Thisresultsintheclassicvarusappearinghip
on X ray. In contrast, some hips may slip in a posterolateral
displacement, producing an apparent valgus deformity and
a so-called valgus SCFE. This occurs when shearing forces
applied to the femoral head exceed the strength of the capital
femoral physis [1]. The exact etiology is unknown, but
is believed to be secondary to multiple factors, including
obesity which increases mechanical strain on the physis.
The periosteal thinning and widening of the physis seen
during rapid adolescent growth acceleration may also be
a predisposing factor for the weakening of the physis [2].
Only small percentage of SCFE (5.2%–6.9%) is associated
with endocrinopathies such as hypothyroidism or growth
hormone deﬁciency [3, 4]. Short stature, early age at
presentation, and the atypical appearance of a valgus SCFE
have all been suggested as indicators for endocrinopathy
screening [5, 6]
We report an interesting case of a 17-year-old normal-
statured female who was diagnosed with congenital panhy-
popituitarism due to pituitary hypoplasia at the presentation
of SCFE.
2. Patient Report
A 17-year-old Caucasian female presented with a 3-month
history of hip pain, diﬃculty walking, and inability to bend
down. She did not have any regular well child care until
this illness. She was born full term with birth weight of 8
lbs and her early development was described as normal. She
washomeschooledbecauseofsomelearningdiﬃculties.Her
mid-parental height was 167.6cm which is at 75th percentile
(+0.67 SD). On physical exam, the patient was 158.1cm tall
(25th%) (Figure 1), and weighed 65kg (75th%). Her body
mass index was 26kg/m2 (90th%). She had bilateral hip pain
with hips held in obligatory external rotation. Hip ﬂexion
was limited to 60 degrees bilaterally. She had waddling gait
and pain with walking. She had Tanner stage 1 for breast and
pubic hair development.2 International Journal of Pediatric Endocrinology
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Figure 1: Growth chart depicts the patient’s growth at diagnosis
and over the course of follow up on growth hormone therapy.
An anteroposterior pelvis radiograph (Figure 2) showed
bilateral, chronic, severe, valgus SCFE, conﬁrmed with CT
scan.ShewasadmittedtoOrthopedicserviceforhipsurgery.
Endocrine service was consulted due to her delayed puberty
and primary amenorrhea. Laboratory studies showed low
free T4 (0.5ng/dL; normal 0.7–2.0), slightly elevated TSH
(7.97µIU/mL; normal 0.5–5.0). FSH 1.3mIU/mL, LH
< 0.5mIU/mL, estradiol < 0.1ng/dL. Pelvic ultrasound
revealed no visualized uterus or ovaries. The ﬁnding of
hypogonadotropic hypogonadism prompted the work up for
hypopituitarism. ACTH stimulation test using 1 microgram
cosyntropin showed low peak cortisol (5.9ug/dL). She was
given stress dose of hydrocortisone prior to her hip surgery
on hospital day 3. Subsequently, complete pituitary eval-
uation showed undetectable IGF-1 level (<25ng/mL), low
IGF-BP3 (1.7mg/dL; normal 3.2–8.7), and low peak growth
hormone (<0.1ng/mL) on growth hormone stimulation test
using arginine and clonidine. Fasting insulin was normal at
15uU/mL. Her bone age (Greulich and Pyle) was delayed at
13 years. Brain MRI showed pituitary hypoplasia, with no
identiﬁable pituitary stalk and ectopic posterior bright spot.
Her pelvic MRI showed no identiﬁable uterus and tiny cystic
structures bilaterally in the lower pelvis that may represent
streak ovaries.
She was treated with levothyroxine, hydrocortisone,
growth hormone, and subsequent estrogen replacement
therapy. Her growth hormone dose was 0.18mg/kg/week
with IGF-1 level within the normal range. Repeat pelvis
ultrasound after 9 months of estrogen therapy revealed
a small uterus and ovaries. After 18 months of growth
hormone therapy, her height increased to 164.5 cm (65th%)
(Figure 1).
3. Discussion
Although only 5.2%–6.9% of patients with SCFE are
associated with endocrinopathy [3, 4], there are some
R
Figure 2: An anteroposterior radiograph of the pelvis revealing
severe, bilateral, valgus slipped capital femoral epiphysis.
clinical characteristics that should alert clinicians to obtain
an endocrinologic evaluation prior to surgical treatment
including: young age at presentation, bilateral disease, and
the presence of a valgus SCFE. This case report highlights
such importance as the patient was found to have pan-
hypopituitarism with adrenal insuﬃciency, the condition
in which without proper perioperative corticosteroid stress
dose coverage, the patient could suﬀer from adrenal crisis
with potential mortality or serious complications.
In a review by Loder et al. of 85 patients with SCFE and
known endocrinopathy, 40% were found to be hypothyroid,
25% were growth hormone deﬁcient, and 35% had other
endocrinopathies such as hypogonadism, hypopituitarism,
hyperparathyroidism, growth hormone excess, and Turner’s
syndrome [4]. In a review by Shank and Klingele, 13 cases
of valgus SCFE were identiﬁed among 257 SCFE cases
presenting to a single hospital, a 5% prevalence [7]. Of the
valgus SCFE patients, 5/13 (38%) had panhypopituitarism
[7]. Age at presentation of SCFE can oﬀer a clue to which
patients should receive an endocrine screening. Typical age
presentation of SCFE is between 10–16 years with the
average 13-14 years for boys and 11-12 years for girls [6].
Patients with hypothyroidism or growth hormone deﬁciency
associated with SCFE are usually younger than 10 years of
age, whereas, those patients with other endocrinopathies
either presented at a typical age or were older than 16 years
of age [4].
The diagnosis of SCFE relative to the time of diagnosis
of the endocrine disorders was diﬀerent depending on the
type of endocrinopathy. Most patients with hypothyroidism
were diagnosed at presentation of SCFE, whereas all of the
growth hormone-deﬁcient patients had the endocrinologic
diagnosis made before presentation of SCFE [4]. In a report
from the National Cooperative Growth Study, Blethen and
Rundle examined the association between SCFE and growth
hormone deﬁciency in a large cohort of 16,514 children.
They found that SCFE developed in 15 children before
they received growth hormone and 26 children developed
SCFE during treatment [8]. In our patient, we do notInternational Journal of Pediatric Endocrinology 3
anticipate a slip progression during the course of growth
hormone therapy, as both hips were treated with a surgical
hip dislocation and osteotomy to correct the severe amount
of slippage, not by traditional pinning with one single screw
where a slip progression can be seen. Once treated in this
manner, the slip will not worsen or recur because the physis
growth plate was removed during the procedure and the
femoral head and neck heal together with a bone union.
Ourpatientpresentedatage-17yearswhichisanatypical
age for presentation. Her bilateral hip involvement and
valgus SCFE presentation also favor the possibility of having
associated endocrinopathy. Her thyroid function test which
showed low free T4 and slightly elevated TSH level may
be misleading as a picture of primary hypothyroidism,
which might not have prompted the extensive work up for
panhypopituitarism. One should keep in mind that slightly
elevated TSH level with low free T4 can be seen in central
hypothyroidism as the primary hormone deﬁciency can be
thyroid-releasing hormone, resulting in diﬀerent TSH levels
that can be normal, low-or slightly elevated.
Our patient’s lack of puberty served as an important
clue to the need of a thorough endocrinologic evaluation.
Her low FSH and LH levels conﬁrmed hypogonadotropic
hypogonadism which led to a complete pituitary hormone
evaluation.Shewasfoundtohavecompletegrowthhormone
deﬁciency with undetectable IGF-1 and growth hormone
levels. Moreover, she was also found to have secondary
adrenal insuﬃciency, as part of her panhypopituitarism.
This ﬁnding has signiﬁcant implication in the management
prior to surgery to prevent potential fatal complication from
adrenal crisis.
Most patients with congenital hypopituitarism present at
youngagewhenshortstatureisnotedduringchildhood.Our
patient had no medical care until her presentation of SCFE
which is a very unusual presenting sign for hypopituitarism.
The interesting and puzzling point in this patient is that
she has a normal stature despite having complete growth
hormone deﬁciency as a result of pituitary hypoplasia
which is a congenital condition. Her infantile uterus and
ovaries (from lack of hormone stimulation) which were
nonvisualized by imaging studies at the time of diagnosis
of panhypopituitarism but later grew in size and were
visualized after estrogen hormone replacement also suggest
that her pituitary hormone deﬁciencies have been present
since birth. This case illustrates growth without growth
hormone syndrome which has been described in literature
[9, 10]. It was postulated that other growth factors such as
leptin, sex hormones, insulin may locally activate the IGF
system in the epiphyseal growth plate [10]. Our patient had
absent sex hormone with normal fasting insulin level. Other
undiscovered hormones and growth factors may have eﬀects
on growth.
In summary, we report an interesting case of a 17-
year-old normal-statured female who was diagnosed with
congenital panhypopituitarism due to pituitary hypoplasia
at the presentation of slipped capital femoral epiphysis. We
emphasized the importance of endocrinologic evaluation in
patients with slipped capital femoral epiphysis that have
signs of endocrinopathy to prevent potential complication
of adrenal crisis during surgery. This case also demonstrates
growthwithoutgrowthhormonewhichresultedinadelayin
diagnosis of congenital hypopituitarism in this patient.
List of Abbreviations
SCFE: Slipped capital femoral epiphysis
TSH: Thyroid stimulating hormone
FSH: Follicle stimulating hormone
LH: Luteinizing hormone
IGF-1: Insulin-like growth factor 1
IGF-BP3: Insulin-like growth factor binding protein 3.
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